Cargando…

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression

SIMPLE SUMMARY: A common characteristic of multiple myeloma (MM) is the dysfunction of patients’ immune system, a condition termed immunosuppression. This state is mainly due to alterations in the number and functionality of the principal immune populations. In this setting, immunotherapy has acquir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz-Tejedor, Andrea, Lorenzo-Mohamed, Mauro, Puig, Noemí, García-Sanz, Ramón, Mateos, María-Victoria, Garayoa, Mercedes, Paíno, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002455/ https://www.ncbi.nlm.nih.gov/pubmed/33802806 http://dx.doi.org/10.3390/cancers13061353

Ejemplares similares

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
por: Mogollón, Pedro, et al.
Publicado: (2019)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA
por: Diaz-Tejedor, A., et al.
Publicado: (2022)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
por: Quwaider, Dalia, et al.
Publicado: (2017)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
por: López-Iglesias, Ana-Alicia, et al.
Publicado: (2017)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2023)

Autophagy: A Potential Therapeutic Target for Reversing Sepsis-Induced Immunosuppression
por: Ren, Chao, et al.
Publicado: (2017)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

Chemotherapy and Immunosuppressant Therapy-Induced Posterior Reversible Encephalopathy Syndrome
por: Kaur, Gurleen, et al.
Publicado: (2020)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
por: Herrero, Ana Belén, et al.
Publicado: (2020)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Is therapeutic hypothermia immunosuppressive?
por: Polderman, Kees H
Publicado: (2012)

Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
por: Rojas, Elizabeta A., et al.
Publicado: (2019)

CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
por: Lewinsky, Hadas, et al.
Publicado: (2021)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies
por: Huang, Boyuan, et al.
Publicado: (2023)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
por: González-Calle, Verónica, et al.
Publicado: (2017)

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
por: Ogiya, Daisuke, et al.
Publicado: (2023)

Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
por: Raja, Karthick Raja Muthu, et al.
Publicado: (2013)

Immunosuppressive peptides and their therapeutic applications()
por: Thell, Kathrin, et al.
Publicado: (2014)

Immunosuppression during Acute Infection with Foot-and-Mouth Disease Virus in Swine Is Mediated by IL-10
por: Díaz-San Segundo, Fayna, et al.
Publicado: (2009)

Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
por: Park, Kevin, et al.
Publicado: (2022)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
por: Chen, Wuzhen, et al.
Publicado: (2021)

Nanocatalytic bacteria disintegration reverses immunosuppression of colorectal cancer
por: Jiang, Han, et al.
Publicado: (2022)

Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma
por: Yu, Su Jong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c8vtqtra46naafljij2e4l5tea